Particle.news
Download on the App Store
6 ARTICLES
·
3w ago

Novo Nordisk’s CagriSema Shows Greater Weight Loss at Lower Doses

Results unveiled at the ADA meeting suggest that a flexible dosing regimen could optimize weight-loss outcomes for many patients.

Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo
Image
Image
Novo Nordisk has not one but three new and distinct weight loss therapeutics

Overview

  • New data show that patients who remained on lower doses of CagriSema lost more weight on average than those who escalated to the highest dose.
  • CagriSema combines Wegovy’s active ingredient semaglutide with cagrilintide to leverage a dual mechanism for appetite and weight control.
  • Safety data presented at the ADA meeting indicate a side-effect profile similar to Wegovy, with dropout rates of about 6% among obesity patients and 8.4% among diabetes patients.
  • Novo Nordisk plans to file for regulatory approval early next year and has launched extended trials to assess the shot’s full weight-loss potential.
  • The company is conducting head-to-head studies against Eli Lilly’s Zepbound and a separate heart-outcome trial to explore cardiovascular benefits.